Eris Lifesciences Ltd (NSE: ERIS) and Pfizer Ltd. (NSE: PFIZER) are both listed in the Pharmaceuticals industry. Eris Lifesciences has a market capitalisation of ₹16,096 Cr and Pfizer ₹16,646 Cr, as of 9 Nov 2026. Their P/E ratios are 25.6 and 23 respectively. Return on equity is 18.07% for Eris Lifesciences and 17.16% for Pfizer. Over one year, Eris Lifesciences's share price is down 21.1% and Pfizer's is down 24.3%.
| Metric | Eris Lifesciences | Pfizer |
|---|---|---|
| NSE Symbol | ERIS | PFIZER |
| BSE Code | 540596 | 500680 |
| Share Price | ₹1,255.50 | ₹3,923.50 |
| Market Cap | ₹16,096 Cr | ₹16,646 Cr |
| P/E Ratio | 25.6 | 23 |
| Return on Equity | 18.07% | 17.16% |
| Return on Assets | 7.30% | 10.77% |
| Dividend Yield | 1.24% | 2.06% |
| Beta (1Y) | 0.07 | 0.34 |
| 1-Year Price Change | -21.1% | -24.3% |
| 3-Month Price Change | -9.9% | -19.6% |
| 52-Week Range | ₹1,069.00 – ₹1,740.00 | ₹3,589.00 – ₹5,339.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹892 Cr | ₹727 Cr |
| Quarterly Net Profit | ₹187 Cr | ₹313 Cr |
| Net Margin | 21.0% | 43.1% |
| EPS (Basic, Quarter) | ₹13.26 | ₹68.47 |
| Results Basis | consolidated | standalone |
| Headquarters | Ahmedabad, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitor…
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was…
Pfizer has a market capitalisation of ₹16,646 Cr, against ₹16,096 Cr for Eris Lifesciences as of 9 Nov 2026, so the two are about the same size by market cap.
Eris Lifesciences has a P/E of 25.6 and Pfizer a P/E of 23 as of 9 Nov 2026.
Eris Lifesciences has a return on equity of 18.07% and Pfizer 17.16%.
Eris Lifesciences's share price is down 21.1% over one year and Pfizer's is down 24.3%.
Eris Lifesciences reported revenue of ₹892 Cr and net profit of ₹187 Cr for Q2 FY27. Pfizer reported revenue of ₹727 Cr and net profit of ₹313 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.